Form 4: Viridian Therapeutics' Chief Legal Officer Receives Stock Options and Restricted Stock Units
SEC Form 4 Filing
Jennifer Tousignant, Chief Legal Officer of Viridian Therapeutics, was granted stock options and restricted stock units on March 3, 2025, according to a Form 4 filing.
Summary
- Jennifer Tousignant, the Chief Legal Officer of Viridian Therapeutics, Inc., received stock options and restricted stock units (RSUs) on March 3, 2025.
- The stock option grants her the right to buy 124,072 shares of common stock at an exercise price of $14.41 per share.
- These options vest in 48 equal monthly installments starting from the grant date, contingent upon her continued service to the company.
- She also received 20,679 RSUs, each representing a contingent right to receive one share of Viridian Therapeutics' common stock.
- The RSUs vest over a four-year period, with 25% vesting annually on each anniversary of the grant date, also subject to continued service.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, incentivizing the Chief Legal Officer. There are no immediate negative implications.
Positives
- The grant of stock options and RSUs aligns the Chief Legal Officer's interests with those of the shareholders.
- The vesting schedules incentivize continued service and commitment to the company's long-term success.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedules of the stock options and RSUs.
Industry Context
Granting stock options and RSUs to key executives is a common practice in the biotechnology industry to attract, retain, and incentivize talent.
Comparison to Industry Standards
- Stock option and RSU grants are standard compensation practices in the biotech industry.
- Companies like Amgen, Gilead, and Regeneron routinely use equity-based compensation to align executive interests with shareholder value.
- The vesting schedules (monthly for options, annual for RSUs) are typical for executive compensation packages.
Stakeholder Impact
- Shareholders may view the equity grants positively as they align management's interests with the company's performance.
- Employees may see this as a positive sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 03/03/2025 | Date of the earliest transaction (grant date for stock options and RSUs) |
| 03/03/2035 | Expiration date of the stock options |
| 03/04/2025 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.